Company Description
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics.
It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery.
The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications.
It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.
The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.
Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Michael Rowe |
Contact Details
Address: 295 Madison Avenue, Suite 2400 New York, New York 10017 United States | |
| Phone | 833 393 6684 |
| Website | eyenovia.com |
Stock Details
| Ticker Symbol | EYEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682639 |
| CUSIP Number | 30234E104 |
| ISIN Number | US30234E1047 |
| Employer ID | 47-1178401 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Rowe | Chief Executive Officer |
| Andrew Jones | Chief Financial Officer |
| Bren Kern | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 424B5 | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 23, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 9, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 424B5 | Filing |
| Dec 4, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 424B5 | Filing |